Our sincerity lies in the attitude with which we work — striving to help bring even one more therapeutic product into the world, so that patients can be treated and more people can smile.
We believe that patent translation is the very first step toward making that future a reality.
In this blog, I will share my personal views on trends and challenges in pharmaceutical research.
If you have any comments or thoughts, please feel free to reach out via the contact form on our website!
【Japan’s RNA Therapeutics: Challenges Today, Big Opportunities Ahead – My View, Part 1】
RNA therapeutics is expanding rapidly around the world, and global innovators are steadily strengthening their patent portfolios.
At the same time, Japan remains an underexplored yet strategically important market — one where deeper engagement can bring significant benefits to both overseas companies and Japan.
RNA therapeutics involves a complex interplay of technologies, including mRNA sequence design, modified nucleic acids, lipid nanoparticles (LNPs), delivery systems, manufacturing processes, stabilization technologies, and administration devices.
Because of this complexity, building a broad, deep, and internationally coordinated patent portfolio is essential.
Strengthening ties with Japan can create advantages for both overseas innovators and Japan itself.
Some of these benefits include the following:
［Benefits for Overseas Companies］
・Securing rights in one of the largest and most stable markets in Asia
・Gaining an early foothold in the Japanese market ahead of competitors
・Filling gaps in global patent portfolios
・Facilitating collaboration with Japanese universities and companies
[Benefits for Japan]
・Increased inflow of overseas technologies, stimulating domestic research
・Enhanced industry–academia collaboration
・Broader therapeutic options for patients in the Japanese market
・Strengthening Japan’s international competitiveness
In Part 2, I will take a closer look at the current state of RNA therapeutics in Japan, drawing on the Patent Office’s “Patent Application Technology Trend Survey Report.